GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Piotroski F-Score

Vectus Biosystems (ASX:VBS) Piotroski F-Score : 3 (As of May. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vectus Biosystems has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Vectus Biosystems's Piotroski F-Score or its related term are showing as below:

ASX:VBS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 4
Current: 3

During the past 8 years, the highest Piotroski F-Score of Vectus Biosystems was 4. The lowest was 2. And the median was 2.


Vectus Biosystems Piotroski F-Score Historical Data

The historical data trend for Vectus Biosystems's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Piotroski F-Score Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Piotroski F-Score
Get a 7-Day Free Trial 2.00 2.00 4.00 2.00 3.00

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.00 - 3.00 -

Competitive Comparison of Vectus Biosystems's Piotroski F-Score

For the Biotechnology subindustry, Vectus Biosystems's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Net Income was A$-3.45 Mil.
Cash Flow from Operations was A$-2.35 Mil.
Revenue was A$0.00 Mil.
Gross Profit was A$0.00 Mil.
Average Total Assets from the begining of this year (Jun22)
to the end of this year (Jun23) was (3.936 + 4.63) / 2 = A$4.283 Mil.
Total Assets at the begining of this year (Jun22) was A$3.94 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.03 Mil.
Total Current Assets was A$4.46 Mil.
Total Current Liabilities was A$1.08 Mil.
Net Income was A$-3.99 Mil.

Revenue was A$0.00 Mil.
Gross Profit was A$0.00 Mil.
Average Total Assets from the begining of last year (Jun21)
to the end of last year (Jun22) was (6.043 + 3.936) / 2 = A$4.9895 Mil.
Total Assets at the begining of last year (Jun21) was A$6.04 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.07 Mil.
Total Current Assets was A$3.73 Mil.
Total Current Liabilities was A$7.40 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vectus Biosystems's current Net Income (TTM) was -3.45. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vectus Biosystems's current Cash Flow from Operations (TTM) was -2.35. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun22)
=-3.449/3.936
=-0.87627033

ROA (Last Year)=Net Income/Total Assets (Jun21)
=-3.994/6.043
=-0.66093

Vectus Biosystems's return on assets of this year was -0.87627033. Vectus Biosystems's return on assets of last year was -0.66093. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Vectus Biosystems's current Net Income (TTM) was -3.45. Vectus Biosystems's current Cash Flow from Operations (TTM) was -2.35. ==> -2.35 > -3.45 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=0.027/4.283
=0.00630399

Gearing (Last Year: Jun22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun21 to Jun22
=0.07/4.9895
=0.01402946

Vectus Biosystems's gearing of this year was 0.00630399. Vectus Biosystems's gearing of last year was 0.01402946. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun23)=Total Current Assets/Total Current Liabilities
=4.457/1.076
=4.14219331

Current Ratio (Last Year: Jun22)=Total Current Assets/Total Current Liabilities
=3.729/7.398
=0.50405515

Vectus Biosystems's current ratio of this year was 4.14219331. Vectus Biosystems's current ratio of last year was 0.50405515. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Vectus Biosystems's number of shares in issue this year was 47.952. Vectus Biosystems's number of shares in issue last year was 33.376. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Vectus Biosystems's gross margin of this year was . Vectus Biosystems's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun22)
=0/3.936
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun21)
=0/6.043
=0

Vectus Biosystems's asset turnover of this year was 0. Vectus Biosystems's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vectus Biosystems has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Vectus Biosystems  (ASX:VBS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Vectus Biosystems Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines